Your browser doesn't support javascript.
loading
A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose­ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis.
Waldbaum, Arthur S; Schwebke, Jane R; Paull, Jeremy R A; Price, Clare F; Edmondson, Stephanie R; Castellarnau, Alex; McCloud, Philip; Kinghorn, George R.
Afiliação
  • Waldbaum AS; Downtown Women's Health Care, Denver, CO, United States of America.
  • Schwebke JR; Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, United States of America.
  • Paull JRA; Starpharma Pty Ltd, Melbourne, VIC, Australia.
  • Price CF; Starpharma Pty Ltd, Melbourne, VIC, Australia.
  • Edmondson SR; Starpharma Pty Ltd, Melbourne, VIC, Australia.
  • Castellarnau A; Starpharma Pty Ltd, Melbourne, VIC, Australia.
  • McCloud P; McCloud Consulting Group, Sydney, NSW, Australia.
  • Kinghorn GR; Royal Hallamshire and Sheffield Teaching Hospitals, Sheffield, United Kingdom.
PLoS One ; 15(5): e0232394, 2020.
Article em En | MEDLINE | ID: mdl-32365097
ABSTRACT

BACKGROUND:

Astodrimer Gel contains a novel dendrimer intended to treat and prevent bacterial vaginosis. We assessed the efficacy and safety of Astodrimer Gel for treatment of bacterial vaginosis.

METHODS:

132 women with bacterial vaginosis were randomized 1111 to Astodrimer 0.5% (N = 34), 1% (N = 33), or 3% (N = 32) Gel or hydroxyethyl cellulose placebo gel (N = 33) at a dose of 5 g vaginally once daily for 7 days at 6 centers in the United States. The primary endpoint was clinical cure (no bacterial vaginosis vaginal discharge and no more than one of 1) vaginal pH ≥4.5; 2) ≥20% clue cells; or 3) positive whiff test) at study days 21-30. Secondary analyses included clinical cure at study days 9-12, patient-reported symptoms, acceptability and adverse events.

RESULTS:

The Astodrimer 1% Gel dose was superior to placebo for the primary and selected secondary efficacy measures in the modified intent-to-treat population. Clinical cure rates at day 9-12 were superior to placebo for the Astodrimer 3%, 1% and 0.5% Gel groups (62.5% [15/24; P = .002], 74.1% [20/27; P < .001], and 55.2% [16/29; P = .001], respectively, vs. 22.2% [6/27]). At day 21-30, clinical cure rates were 46.2% (12/26) for the 1% dose vs. 11.5% for placebo (3/26; P = .006). A greater proportion of patients reported absence of vaginal discharge and vaginal odor at day 9-12 and day 21-30 for Astodrimer Gel groups compared with placebo. Adverse events considered potentially treatment-related occurred in only 25% of Astodrimer Gel-treated patients vs. 22% of placebo patients.

CONCLUSION:

Astodrimer Gel once daily for 7 days was superior to placebo for treatment of bacterial vaginosis and was well-tolerated. The 1% dose consistently showed the strongest efficacy across endpoints. These results support a role for Astodrimer Gel, 1%, as an effective treatment for bacterial vaginosis.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polilisina / Vaginose Bacteriana / Descarga Vaginal / Dendrímeros / Antibacterianos Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polilisina / Vaginose Bacteriana / Descarga Vaginal / Dendrímeros / Antibacterianos Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos